Business Context and Reporting Period
This Form 8-K, filed on August 29, 2021, by Petra Acquisition Inc. (Petra), announces the entry into a definitive Merger Agreement with Revelation Biosciences, Inc. (Revelation). Under the agreement, a wholly-owned subsidiary of Petra will merge with and into Revelation, with Revelation surviving as a wholly-owned subsidiary of Petra. Upon consummation, Petra will be renamed "Revelation Biosciences, Inc." The transaction is structured as a business combination where Petra acquires all outstanding equity interests of Revelation.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or margin data for either entity. Key financial terms of the transaction include:
- Merger Consideration: Petra has agreed to acquire Revelation for an aggregate of 10,500,000 shares of Petra Common Stock.
- Exchange Ratio: The consideration is calculated based on a "Common Stock Exchange Ratio," defined as the quotient of the Merger Consideration Shares divided by the "Fully Diluted Company Shares" of Revelation (including common stock, preferred stock on an as-converted basis, rollover warrant shares, and rollover RSU shares).
- Net Tangible Assets Requirement: A closing condition requires the combined company ("New Revelation") to have at least $5,000,001 of net tangible assets immediately following the closing, after accounting for any redemptions of public shares by Petra stockholders.
- Warrant Conversion: Existing Revelation warrants will convert into Petra warrants with adjusted share counts and exercise prices based on the Common Stock Exchange Ratio.
Material Changes and Transaction Structure
The primary material change is the proposed business combination between a Special Purpose Acquisition Company (SPAC) and a private biotechnology firm. Key structural elements include:
- Board Composition: Post-closing, the board will consist of five directors: James Rolke, George F. Tidmarsh, MD, PhD, Jennifer Carver, Jess Roper, and Curt LaBelle, MD.
- Management Transition: All current Petra executive officers will resign at closing, and the executive officers of Revelation will assume the same roles in the combined company.
- Extension of Deadline: Petra must extend its deadline to consummate a business combination from October 13, 2021, to January 13, 2022, via a stockholder vote on an Extension Proposal.
- Lock-Up Agreement: Certain Revelation stockholders will be subject to a six-month lock-up period post-closing, restricting the sale or transfer of their shares.
Guidance, Outlook, Risks, and Contingencies
The filing contains extensive forward-looking statements regarding the anticipated benefits, integration, and future performance of the combined company, but provides no specific financial guidance or revenue projections. Key risks and contingencies identified include:
- Closing Conditions: The transaction is contingent upon stockholder approval from Petra, absence of a Material Adverse Effect, meeting the $5,000,001 net tangible asset threshold, Nasdaq listing approval, and delivery of lock-up agreements.
- Redemption Risk: There is uncertainty regarding the amount of cash remaining in Petra's trust account if public stockholders exercise their right to redeem shares, which could impact the cash available to Revelation for operations and R&D.
- Regulatory and Clinical Risks: Risks include the successful development of product candidates (specifically REVTx-99), clinical trial outcomes, regulatory approval from the FDA/EMA, and the clinical utility of intranasal IP-10 levels.
- Termination Rights: The agreement may be terminated by mutual consent or if the closing does not occur by the extended deadline (January 13, 2022).
Investor Verification Checklist
- Verify the final "Fully Diluted Company Shares" count to determine the precise Common Stock Exchange Ratio and value of the merger consideration.
- Monitor the upcoming proxy statement (Form S-4) for details on the Extension Proposal and the specific redemption rights of Petra public stockholders.
- Confirm the projected cash balance in the trust account post-redemption to assess if it meets the $5,000,001 net tangible asset requirement and suffices for Revelation's operational runway.
- Review the definitive proxy statement for the full list of risks, including specific clinical trial timelines and regulatory hurdles for Revelation's product pipeline.
- Check for any updates on the Nasdaq listing approval status for the combined entity.